Author(s)
Greg McInnes
Published 5 Projects
genomics Bioinformatics Genetics Health Systems And Quality Improvement
Russ Altman
Published 17 Projects
Through Manual Identification And Other In The United States In This Paper Singapore
Content
Video Abstract (AI generated) (02:27) Paper Preprint Supplemental File 1 Supplemental FiguresGenetics plays a key role in drug response, affecting efficacy and toxicity. Pharmacogenomics aims to understand how genetic variation influences drug response and develop clinical guidelines to aid clinicians in personalized treatment decisions informed by genetics. Although pharmacogenomics has not been broadly adopted into clinical practice, genetics influences treatment decisions regardless. Physicians adjust patient care based on observed response to medication, which may occur as a result of genetic variants harbored by the patient. Here we seek to understand the genetics of drug selection in statin therapy, a class of drugs widely used for high cholesterol treatment. Genetics are known to play an important role in statin efficacy and toxicity, leading to significant changes in patient outcome. We performed genome-wide association studies (GWAS) on statin selection among 59,198 participants in the UK Biobank and found that variants known to influence statin efficacy are significantly associated with statin selection. Specifically, we find that carriers of variants in APOE and LPA that are known to decrease efficacy of treatment are more likely to be on atorvastatin, a stronger statin. Additionally, carriers of the APOE and LPA variants are more likely to be on a higher intensity dose (a dose that reduces low‑density lipoprotein cholesterol by greater than 40%) of atorvastatin than non-carriers (APOE: p(high intensity) = 0.16, OR = 1.7, P = 1.64 x 10-4, LPA: p(high intensity) = 0.17, OR = 1.4, P = 1.14 x 10-2). These findings represent the largest genetic association study of statin selection and statin dose association to date and provide evidence for the role of LPA and APOE in statin response, furthering the possibility of personalized statin therapy. ### Competing Interest Statement R.B.A. is a stockholder in Personalis.com, 23andme.com. M.A.R. is on the SAB of 54Gene and Computational Advisory Board for Goldfinch Bio and has advised BioMarin, Third Rock Ventures, MazeTx and Related Sciences.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 3 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 3 years ago
Jignesh H. Parmar
0 views • 2 years ago
Winston A. Haynes
0 views • 2 years ago
Noam Mazor
0 views • 2 years ago
Global Immunotalks
182 views • 3 years ago
Cem Yuksel
345 views • 2 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Russ Altman. (2021, Oct 26).LPA and APOE are associated with statin selection in the UK Biobank[Video]. Scitok. https://scitok.com/project/p/38de93be
Lavertu Adam. "LPA and APOE are associated with statin selection in the UK Biobank" Scitok, uploaded by Altman Russ, 26 Oct, 2021, https://scitok.com/project/p38de93be
Russ Altman. "LPA and APOE are associated with statin selection in the UK Biobank" Scitok. (Oct 26, 2021). https://scitok.com/project/p/38de93be
Russ Altman (Oct 26, 2021). LPA and APOE are associated with statin selection in the UK Biobank Scitok. https://scitok.com/project/p/38de93be
Russ Altman. LPA and APOE are associated with statin selection in the UK Biobank[video]. 2021 Oct 26. https://scitok.com/project/p/38de93be
@online{al2006link, title={ LPA and APOE are associated with statin selection in the UK Biobank }, author={ Altman, Russ }, organization={Scitok}, month={ Oct }, day={ 26 }, year={ 2021 }, url = {https://scitok.com/project/p/38de93be}, }